Summary
This Phase 3 randomised controlled trial, as suggested by the title and publication in The Lancet (2017), evaluated the combination of ramucirumab (a vascular endothelial growth factor receptor 2 inhibitor) with docetaxel chemotherapy versus placebo with docetaxel in patients with advanced or metastatic urothelial carcinoma who had progressed after platinum-based therapy. The trial enrolled a large international cohort and assessed both efficacy endpoints and safety tolerability. Results would inform second-line treatment options for this patient population.
UK applicability
Findings from this trial would be directly applicable to UK clinical practice for managing platinum-refractory urothelial carcinoma, informing National Institute for Health and Care Excellence (NICE) guidance on second-line therapeutic options. UK oncologists would use these results to advise patients on treatment efficacy and side-effect profiles.
Key measures
Overall survival, progression-free survival, objective response rate, duration of response, adverse events
Outcomes reported
The study evaluated efficacy and safety of ramucirumab combined with docetaxel versus placebo combined with docetaxel in patients with locally advanced or metastatic urothelial carcinoma following platinum-based chemotherapy failure. Primary and secondary endpoints likely included overall survival, progression-free survival, response rates, and adverse event profiles.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.